BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $74.47, for a total value of $279,262.50. Following the transaction, the director now directly owns 27,340 shares in the company, valued at $2,036,009.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ BMRN traded down $0.33 on Thursday, reaching $75.17. The stock had a trading volume of 12,874 shares, compared to its average volume of 955,794. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.11 and a quick ratio of 2.79. The firm has a fifty day moving average of $75.31 and a two-hundred day moving average of $83.43. BioMarin Pharmaceutical Inc. has a 1-year low of $70.82 and a 1-year high of $106.74. The company has a market cap of $13.53 billion, a P/E ratio of -226.89 and a beta of 1.32.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The firm had revenue of $388.00 million during the quarter, compared to analyst estimates of $415.03 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. Research analysts predict that BioMarin Pharmaceutical Inc. will post -0.03 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Rational Advisors LLC grew its holdings in BioMarin Pharmaceutical by 3,211.1% in the 1st quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 289 shares in the last quarter. Doyle Wealth Management bought a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $26,000. Berman Capital Advisors LLC lifted its position in shares of BioMarin Pharmaceutical by 56.8% during the 1st quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 151 shares during the period. Twin Tree Management LP bought a new stake in shares of BioMarin Pharmaceutical during the 1st quarter valued at $36,000. Finally, Avestar Capital LLC lifted its position in shares of BioMarin Pharmaceutical by 36.9% during the 2nd quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 202 shares during the period. 97.93% of the stock is currently owned by hedge funds and other institutional investors.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Story: Why is the conference call important?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.